
Caterina Veroni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5287945/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sex-based differences in autoimmune diseases. Annali Dell'Istituto Superiore Di Sanita, 2016, 52, 205-12.	0.2	196
2	Epstein-Barr Virus Latent Infection and BAFF Expression in B Cells in the Multiple Sclerosis Brain: Implications for Viral Persistence and Intrathecal B-Cell Activation. Journal of Neuropathology and Experimental Neurology, 2010, 69, 677-693.	0.9	135
3	B-Cell Enrichment and Epstein-Barr Virus Infection in Inflammatory Cortical Lesions in Secondary Progressive Multiple Sclerosis. Journal of Neuropathology and Experimental Neurology, 2013, 72, 29-41.	0.9	98
4	Activation of TNF receptor 2 in microglia promotes induction of anti-inflammatory pathways. Molecular and Cellular Neurosciences, 2010, 45, 234-244.	1.0	93
5	Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism. Journal of Virology, 2019, 93, .	1.5	67
6	Transcriptional profile and Epstein-Barr virus infection status of laser-cut immune infiltrates from the brain of patients with progressive multiple sclerosis. Journal of Neuroinflammation, 2018, 15, 18.	3.1	60
7	The CD8 T Cell-Epstein-Barr Virus-B Cell Trialogue: A Central Issue in Multiple Sclerosis Pathogenesis. Frontiers in Immunology, 2021, 12, 665718.	2.2	38
8	Megalencephalic leukoencephalopathy with subcortical cysts protein-1 regulates epidermal growth factor receptor signaling in astrocytes. Human Molecular Genetics, 2016, 25, 1543-1558.	1.4	32
9	RORÎ ³ t Expression and Lymphoid Neogenesis in the Brain of Patients with Secondary Progressive Multiple Sclerosis. Journal of Neuropathology and Experimental Neurology, 2016, 75, 877-888.	0.9	31
10	A staged screening of registered drugs highlights remyelinating drug candidates for clinical trials. Scientific Reports, 2017, 7, 45780.	1.6	31
11	β-dystrobrevin, a kinesin-binding receptor, interacts with the extracellular matrix components pancortins. Journal of Neuroscience Research, 2007, 85, 2631-2639.	1.3	24
12	Epstein-Barr virus-associated immune reconstitution inflammatory syndrome as possible cause of fulminant multiple sclerosis relapse after natalizumab interruption. Journal of Neuroimmunology, 2018, 319, 9-12.	1.1	21
13	Megalencephalic Leukoencephalopathy with Subcortical Cysts Protein-1 (MLC1) Counteracts Astrocyte Activation in Response to Inflammatory Signals. Molecular Neurobiology, 2019, 56, 8237-8254.	1.9	19
14	Association of Dystrobrevin and Regulatory Subunit of Protein Kinase A: A New Role for Dystrobrevin as a Scaffold for Signaling Proteins. Journal of Molecular Biology, 2007, 371, 1174-1187.	2.0	18
15	Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis. Journal of Neuroinflammation, 2015, 12, 132.	3.1	18
16	HIV-1 Myristoylated Nef Treatment of Murine Microglial Cells Activates Inducible Nitric Oxide Synthase, NO2 Production and Neurotoxic Activity. PLoS ONE, 2015, 10, e0130189.	1.1	14
17	Connecting Immune Cell Infiltration to the Multitasking Microglia Response and TNF Receptor 2 Induction in the Multiple Sclerosis Brain. Frontiers in Cellular Neuroscience, 2020, 14, 190.	1.8	10
18	Oxidative Status in Multiple Sclerosis and Off-Targets of Antioxidants: The Case of Edaravone. Current Medicinal Chemistry, 2020, 27, 2095-2105.	1.2	6